Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.

Abstract

Current guidelines from the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommend first-line treatment with a thiazide diuretic but do not provide specific guidance for obese patients. The renin system is activated in obesity-associated arterial hypertension. Therefore, we tested the hypothesis that the oral direct renin inhibitor aliskiren could provide additive blood pressure lowering in obese patients with hypertension (body mass index >or=30 kg/m(2); mean sitting diastolic blood pressure: 95 to 109 mm Hg) who had not responded to 4 weeks of treatment with hydrochlorothiazide (HCTZ) 25 mg. After a 2- to 4-week washout, 560 patients received single-blind HCTZ (25 mg) for 4 weeks; 489 nonresponders were randomly assigned to double-blind aliskiren (150 mg), irbesartan (150 mg), amlodipine (5 mg), or placebo for 4 weeks added to HCTZ (25 mg), followed by 8 weeks on double the initial doses of aliskiren, irbesartan, or amlodipine. After 8 weeks of double-blind treatment (4 weeks on the higher dose), aliskiren/HCTZ lowered blood pressure by 15.8/11.9 mm Hg, significantly more (P<0.0001) than placebo/HCTZ (8.6/7.9 mm Hg). Aliskiren/HCTZ provided blood pressure reductions similar to those with irbesartan/HCTZ and amlodipine/HCTZ (15.4/11.3 and 13.6/10.3 mm Hg, respectively), with similar tolerability to placebo/HCTZ. Adverse event rates were highest with amlodipine/HCTZ because of a higher incidence of peripheral edema (11.1% versus 0.8% to 1.6% in other groups). In conclusion, combination treatment with aliskiren is a highly effective and well-tolerated therapeutic option for obese patients with hypertension who fail to achieve blood pressure control with first-line thiazide diuretic treatment.

• Authors: Jens Jordan, Stefan Engeli, Sam W Boye, Stephanie Le Breton, Deborah L Keefe
• Journal: Hypertension (Dallas, Tex. : 1979) (Hypertension) Vol. 49 Issue 5 Pg. 1047-55 (May 2007) ISSN: 1524-4563 [Electronic] United States
• PMID: 17353513 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Amides
• Antihypertensive Agents
• Biphenyl Compounds
• Fumarates
• Tetrazoles
• Hydrochlorothiazide
• Amlodipine
• aliskiren
• Renin
• Irbesartan

Topics

• Administration, Oral
• Adult
• Aged
• Amides (administration & dosage, adverse effects, therapeutic use)
• Amlodipine (adverse effects, therapeutic use)
• Antihypertensive Agents (adverse effects, therapeutic use)
• Biphenyl Compounds (adverse effects, therapeutic use)
• Blood Pressure (drug effects)
• Diastole
• Double-Blind Method
• Female
• Fumarates (administration & dosage, adverse effects, therapeutic use)
• Humans
• Hydrochlorothiazide (adverse effects, therapeutic use)
• Hypertension (blood, complications, drug therapy, physiopathology)
• Irbesartan
• Male
• Middle Aged
• Obesity (complications)
• Renin (antagonists & inhibitors, blood)
• Systole
• Tetrazoles (adverse effects, therapeutic use)
• Treatment Outcome